SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.17M | 13.40M | 9.73M | 8.97M | 7.00M |
| Gross Profit | -16.17M | -13.40M | -9.73M | -8.97M | -7.00M |
| SG&A Expenses | 7.21M | 6.60M | 6.04M | 3.71M | 2.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.38M | 20.00M | 15.77M | 12.68M | 9.73M |
| Operating Income | -23.38M | -20.00M | -15.77M | -12.68M | -9.73M |
| Income Before Tax | -22.49M | -18.87M | -16.86M | 45.45M | -10.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.49M | -18.87M | -16.86M | 45.45M | -10.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.49M | -18.87M | -16.86M | 45.45M | -10.11M |
| EBIT | -23.38M | -20.00M | -15.77M | -12.68M | -9.73M |
| EBITDA | -22.54M | -19.25M | -15.01M | -11.91M | -8.96M |
| EPS Basic | -0.28 | -0.35 | -0.06 | 0.50 | -1.09 |
| Normalized Basic EPS | -0.18 | -0.22 | -0.22 | 2.66 | -0.68 |
| EPS Diluted | -0.28 | -0.35 | -0.25 | -0.21 | -1.09 |
| Normalized Diluted EPS | -0.18 | -0.22 | -0.22 | 0.36 | -0.68 |
| Average Basic Shares Outstanding | 79.75M | 53.56M | 48.00M | 10.66M | 9.29M |
| Average Diluted Shares Outstanding | 79.75M | 53.56M | 48.00M | 77.86M | 9.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |